MichaelKennethKengMD

Oncology • Charlottesville, VA

Hematologic Oncology

Physician

Join to view full profile

Dr. Keng is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Keng's full profile

Already have an account?

Office
1240 Lee St
Charlottesville, VA 22908
Phone+1 434-924-9333

Fax+1 434-243-6086

Education & Training

Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2011 - 2014
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2007 - 2010
Michigan State University College of Human MedicineClass of 2007

Certifications & Licensure

CA State Medical License 2008 - Present
VA State Medical License 2014 - 2026
MI State Medical License 2010 - 2014
OH State Medical License 2011 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis Start of enrollment: 2018 Jan 26
Completed
Phase 2

Publications & Presentations

PubMed

Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia.
Joseph F Mort, David Brighton, Samantha DiBenedetto, Leah Wells, Stephen M Clark
European Journal of Haematology. 2024-11-27
1 citations
MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications.
Valerie Tran, Kiarash Salafian, Kenan Michaels, Caroline Jones, Daniel Reed
Current Hematologic Malignancy Reports. 2024-08-01
2 citations
Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study.
Guillermo Garcia-Manero, Maciej Kazmierczak, Agnieszka Wierzbowska, Chun Yew Fong, Michael K Keng
Leukemia Research. 2024-05-01

Abstracts/Posters

Distance Does Not Matter: Excellent Survival Outcomes for Leukemia Patients in Rural Appalachia
Michael K Keng, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...
Michael Keng, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Oral Regimen for Urine Alkalization in Patients Receiving High Dose Methotrexate during a National Shortage of Intravenous Sodium Bicarbonate
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

It's Time to Take Action on Quality Improvement MeasuresOctober 21st, 2016
Download Clinical Vignette and Research Abstract CompendiumJanuary 16th, 2018